Voloridge Investment Management LLC acquired a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 39,063 shares of the company's stock, valued at approximately $749,000. Voloridge Investment Management LLC owned about 0.06% of Arvinas at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. KBC Group NV raised its holdings in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after acquiring an additional 1,255 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Arvinas during the fourth quarter worth $171,000. Tema Etfs LLC purchased a new stake in shares of Arvinas in the fourth quarter valued at $227,000. Teacher Retirement System of Texas increased its stake in Arvinas by 19.0% in the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock valued at $274,000 after purchasing an additional 2,280 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in Arvinas by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company's stock worth $279,000 after buying an additional 1,367 shares during the period. Hedge funds and other institutional investors own 95.19% of the company's stock.
Insider Transactions at Arvinas
In other news, insider Noah Berkowitz sold 8,658 shares of Arvinas stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. This trade represents a 7.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.73% of the company's stock.
Analyst Ratings Changes
ARVN has been the topic of several research analyst reports. Leerink Partnrs cut shares of Arvinas from a "strong-buy" rating to a "hold" rating in a research report on Sunday. Bank of America decreased their price target on shares of Arvinas from $54.00 to $28.00 and set a "buy" rating on the stock in a report on Wednesday, March 12th. Truist Financial restated a "hold" rating and set a $11.00 price objective (down from $21.00) on shares of Arvinas in a report on Monday, May 5th. Morgan Stanley reduced their target price on Arvinas from $12.00 to $11.00 and set an "equal weight" rating on the stock in a report on Friday, May 9th. Finally, Jefferies Financial Group restated a "hold" rating and set a $10.00 price target (down from $52.00) on shares of Arvinas in a research note on Friday, May 2nd. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $20.29.
View Our Latest Stock Analysis on Arvinas
Arvinas Trading Down 1.1%
NASDAQ ARVN traded down $0.08 during mid-day trading on Tuesday, reaching $7.25. 523,213 shares of the company's stock traded hands, compared to its average volume of 2,253,858. The company has a fifty day simple moving average of $7.31 and a 200-day simple moving average of $14.45. Arvinas, Inc. has a 1-year low of $5.90 and a 1-year high of $34.11. The company has a market cap of $529.18 million, a price-to-earnings ratio of -2.62 and a beta of 2.21.
Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. The firm's revenue was up 646.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.97) EPS. Equities research analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.
About Arvinas
(
Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Further Reading
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
